JORGE ALBERTO VILLANUA BERNUÉS-rekin lankidetzan egindako argitalpenak (13)

2022

  1. Brief cognitive test as a decision tool in Primary Care settings. Population and validation study

    Neurologia

2021

  1. Plasma lipids are associated with white matter microstructural changes and axonal degeneration

    Brain Imaging and Behavior, Vol. 15, Núm. 2, pp. 1043-1057

2020

  1. Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-β42 and White Matter Microstructure in Cognitively Healthy Adults

    Journal of Alzheimer's disease : JAD, Vol. 76, Núm. 2, pp. 643-656

2018

  1. Cortical microstructural changes along the Alzheimer's disease continuum

    Alzheimer's and Dementia, Vol. 14, Núm. 3, pp. 340-351

  2. Functional brain network centrality is related to APOE genotype in cognitively normal elderly

    Brain and Behavior, Vol. 8, Núm. 9

  3. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults

    Neurology, Vol. 91, Núm. 3, pp. e217-e226

2017

  1. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition

    Neurobiology of Aging, Vol. 50, pp. 144-151

  2. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum

    Neurobiology of Aging, Vol. 53, pp. 192.e1-192.e4

2016

  1. Gray matter network disruptions and amyloid beta in cognitively normal adults

    Neurobiology of Aging, Vol. 37, pp. 154-160

  2. Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults

    Neurobiology of Aging, Vol. 38, pp. 14-20

  3. MTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

    Expert Opinion on Therapeutic Targets, Vol. 20, Núm. 4, pp. 393-405

  4. Targeting SOX2 as a therapeutic strategy in glioblastoma

    Frontiers in Oncology

2013

  1. Therapeutic strategies targeting Glioblastoma stem cells

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Núm. 3, pp. 216-227